More than two-thirds of deaths from ovarian cancer are attributable to high-grade serous carcinoma. In one particularly ...

A multitargeted T-cell therapy produced encouraging activity in a preliminary study of patients with pancreatic cancer, ...

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T ...

Patient-reported fatigue prior to cancer treatment could be used as a biomarker for identifying which individuals will develop serious or fatal adverse events.A retrospective analysis showed patients ...

We’re starting to understand more that endometrial cancer harbors a number of cell surface markers, including folate receptor ...

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...

Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...

Suvemcitug combined with chemotherapy significantly improved PFS and OS in platinum-resistant recurrent ovarian cancer, nearly doubling median PFS and extending median OS. The trial demonstrated ...

Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.

VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual tumor marker designed to provide artifact-free visibility across all major breast imaging ...

Enhanced chemosensitivity: Laboratory data suggest PRP makes resistant pancreatic tumor cells more responsive to standard chemotherapies and alters the tumor microenvironment — including reduced ...

Baseline fatigue before cancer treatment is linked to higher risks of severe and fatal toxic effects, suggesting patient ...